Actions of the National Regulatory Authorities in Developing Countries Following US FDA and EMA Safety Alerts on Rosiglitazone

被引：0
|
作者：
Nwokike, Jude I. [1 ]
Stergachis, Andy [2 ]
机构：
[1] Management Sci Hlth, Strengthening Pharmaceut syst, Arlington, VA USA
[2] Univ Washington, Sch Publ Hlth, Washington, WA USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2011年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
502
引用
收藏
页码：S219 / S219
页数：1
相关论文
共 4 条
  • [1] Actions of the National Regulatory Authorities in 10 Low- and Middle-Income Countries Following Stringent Regulatory Authority Safety Alerts on Rosiglitazone
    Jude Nwokike
    Lassane Kabore
    Andy Stergachis
    Therapeutic Innovation & Regulatory Science, 2015, 49 : 279 - 283
  • [2] Actions of the National Regulatory Authorities in 10 Low- and Middle-Income Countries Following Stringent Regulatory Authority Safety Alerts on Rosiglitazone
    Nwokike, Jude
    Kabore, Lassane
    Stergachis, Andy
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2015, 49 (02) : 279 - 283
  • [3] Pharmacovigilance regulatory actions by national pharmacovigilance centers in Arab countries following COVID-19 pandemic
    Al-Zubiedi, Sameh A.
    Younus, Manal
    Al-Khalidi, Sara
    Ekilo, Magnus
    Alshammari, Thamir M.
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (02) : 165 - 174
  • [4] Pharmacovigilance Regulatory Actions by National Pharmacovigilance Centres in Fourteen Middle Eastern Countries Following COVID-19 Pandemic
    Zubiedi, S. A.
    Younus, M.
    Khalidi, S. A.
    Ekilo, M.
    Alshammari, T.
    DRUG SAFETY, 2022, 45 (10) : 1175 - 1176
1